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Introduction
Coronavirus disease 19 (COVID-19) is a highly transmis-
sible viral infection caused by severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), which emerged 
in Wuhan, China and has since spread rapidly around the 
world. Coronaviruses are so named for their characteristic 
crown-like appearance and are widespread in nature infect-
ing several different species causing mainly respiratory and 
enteric pathology [1].
SARS-CoV-2 is the seventh coronavirus known to infect 
humans; whereas four are endemic (HKU1, NL63, OCw43 
and 229E) and cause a considerable share of mild upper and 
lower respiratory tract infections, SARS-CoV, MERSCoV 
and SARS-CoV-2 can cause severe disease [2]. The spec-
trum of pathology in COVID-19 is wide and ever increasing 
with a burgeoning number of case reports and case series 
published on a daily basis that provide some preliminary 
insights to the disease and its complications. However, it is 
certain that larger case series and population-based studies 
will follow, as is the usual pattern with novel diseases. In this 
month’s journal club, and in a break from the normal for-
mat, we have attempted to provide an early snapshot of the 
current literature describing neurological manifestations of 
this novel disease in a very fast moving subject area, but in 
the certain knowledge that this will be superseded in due 
course by more comprehensive studies.
Neurological manifestations of COVID‑19
As of the 1st May 2020, there have been 52 data papers com-
prising case reports or case series and 27 reviews including 
editorials/position papers. In January 2020, a retrospective, 
single-center study on 99 patients diagnosed with SARS-
COV-2 pneumonia at a hospital in Wuhan identified confu-
sion and headache in 9% and 8%, respectively [3]. A recently 
published retrospective, observational study from Wuhan in 
214 patients with RT-pPCR confirmed COVID-19 reported 
36% had neurologic manifestations [4]; central nervous sys-
tem (CNS) 25%, peripheral nervous system (PNS) 9% and 
skeletal muscle injury 11%. In patients with CNS manifesta-
tions, the most commonly reported symptoms were dizziness 
(17%) and headache (13%). In patients with PNS symptoms, 
the commonest were dysgeusia 6% and hyposmia 5%. CNS 
symptoms were also more commonly identified in those with 
severe disease with associated thrombocytopenia, increased 
urea levels and lymphopenia.
A study of patients admitted to intensive care units (ITU) 
has also emphasized the frequency of neurological features 
[5]. In an observational series of 58 of 64 consecutive 
patients admitted to hospital with acute respiratory distress 
syndrome (ARDS) secondary to COVID-19, 40 (69%) dis-
played agitation and 39 (67%) exhibited diffuse corticospinal 
tract signs with enhanced tendon reflexes, ankle clonus, and 
bilateral extensor plantar reflexes. Of the patients who had 
been discharged by the time of publication, 15/45 (33%) 
were noted to have a dysexecutive syndrome consisting of 
inattention, disorientation, or poorly organized movements 
in response to command. However, in the seven patients 
who underwent CSF analysis, RT-PCR for SARS-CoV-2 
was negative in all cases.
In addition to neurological symptoms accompanying the 
classical respiratory presentation of COVID-19, case reports 
and series have identified a wide range of acute clinical 
neurological syndromes which largely fall into three main 
categories: stroke, Guillain–Barré Syndrome (GBS) and 
variants and meningoencephalitis/encephalopathy/encepha-
litis. There are also a smaller numbers of studies reporting 
 * N. P. Robertson 
 robertsonnp@cardiff.ac.uk
1 Division of Psychological Medicine and Clinical 
Neuroscience, Department of Neurology, Cardiff 
University, University Hospital of Wales, Heath Park, 
Cardiff CF14 4XN, UK
1871Journal of Neurology (2020) 267:1870–1873 
1 3
epilepsy (n = 3), acute disseminated encephalomyelitis 
(ADEM) and acute myelitis. In addition there are reports of 
psychiatric and neuropsychiatric presentations which are not 
reviewed in this article.
Stroke
Of 12 reports published up to the 1st May 2020, 5 were sin-
gle case reports, 4 were case series (reporting between 2 and 
6 cases), 2 were observational studies describing the inci-
dence of CVA in patients positive for RT-PCR for SARS-
CoV-2, whilst a further study is a meta-analysis of four stud-
ies which reported that patients with a history of stroke have 
an increased odds ratio of 2.5 for developing severe COVID-
19 [6]. The two observational studies describe case series 
of patients with COVID-19. In the first retrospective study 
of 221 patients, 11 (5%) developed acute ischemic stroke, 
1 (0·5%) cerebral venous sinus thrombosis (CVST), and 1 
(0·5%) cerebral hemorrhage [7]. In the second prospective 
study of 288 patients, ischemic stroke was diagnosed in 9 
(2.5%) of included patients [8].
These 9 case reports and case series together detail a total 
of 21 patients; [9–17] 16 males and 5 females. Age was pre-
cisely stated in 20 cases and was a mean of 59.8 years (male-
63.1, female-49.8), although may be artificially depressed 
by the case series of young strokes [12]. The majority (19) 
were ischemic strokes, although three underwent hemor-
rhagic transformation, whilst 2 were hemorrhagic at onset. 
Of the 19 ischemic cases, 8 had multiple infarcts. Thirteen 
patients had thrombus detectable on imaging; 6 within the 
middle cerebral, 2 posterior cerebral, three vertebral/basi-
lar and 1 internal carotid. A further case had multiple sites 
of thrombus. Of the remainder, four were consistent with 
large-vessel occlusions but the presence of thrombus was not 
explicitly stated; the remaining two were lacunar infarcts. 
Several of the reports note other thrombotic events; four 
patients had pulmonary emboli (three bilateral), one patient 
presented with myocardial infarction and ischemic limbs, 
while ischemic limbs and renal infarction were also noted 
in other cases. Of the 19 patients with ischemic stroke, four 
patients died, six were still supported on an intensive care 
unit (ICU), one remained on a stroke unit, two were at a 
stroke rehabilitation facility and five made a good recovery. 
Outcome in one case was not stated.
Also of interest, significantly elevated D-Dimer levels 
(≥ 1000 μg/L) were reported in 14 cases, of which nine had 
anticardiolipin antibodies and lupus anticoagulant tests with 
variable results. In a series of six patients from the UK, one 
patient had medium titre for IgM anticardiolipin antibodies 
and lupus anticoagulant was positive in five of six cases 
[10]. However in a series of three patients from Beijing, all 
patients were positive for anticardiolipin IgA antibodies as 
well as anti-β2-glycoprotein I IgA and IgG antibodies but 
lupus anticoagulant was not detected in any patients [13].
Guillain‑Barré Syndrome and variants
Of 8 reports published by 1st of May 2020, 6 were sin-
gle case reports [18–23] and 2 were case series (n = 2–5) 
[24, 25] describing a total of 13 para-COVID-19 or post 
COVID-19 GBS (10 males, 3 females, mean age 58.9; male 
55.8, female 69.7). Eleven were positive for SARS-COV-2 
RT-qPCR from oropharyngeal swabs. Two were RT-qPCR 
negative; one presented 24 days after COVID-19 respira-
tory symptoms but with typical CT chest abnormalities [19] 
and one where the GBS presentation preceded respiratory 
symptoms by 8 days [23].
Eleven cases presented with progressive a flexic flaccid 
tetraparesis of whom five developed bilateral facial weak-
ness and seven required intubation and ventilation. Two 
cases presented with a Miller Fisher variant [25]. Neuro-
logical symptoms developed between 3 and 28 days after 
emergence of respiratory symptoms at a median interval of 
11 days. Twelve of the 13 cases were treated with IVIG. At 
4 weeks, two patients required ongoing mechanical ventila-
tion in ITU, three were undergoing rehabilitation, four had 
been discharged and one had died. Outcomes for the remain-
ing three patients are unknown.
Lumbar puncture was performed on 11 patients from 
day 1 to 5 of neurological symptoms; white cells were typi-
cally normal or mildly raised (1–9/μL in 5 cases), protein 
was within normal range in 3 cases and > 45 mg/dL in the 
remaining 8 cases (range 48–193 mg/dL; average 104.6 mg/
dL). Eight had CSF tested for SARS-COV2 PCR all of 
which were negative. Ten had neurophysiological examina-
tions between day 3 and 12 of neurological symptoms; 6 
showed changes consistent with demyelination and 4 with 
axonal variant GBS. Anti-ganglioside antibodies results 
were reported in only four; three were negative whilst a 
patient with Miller Fisher presentation had positive GD1b 
antibody but negative GQ1b [25].
Encephalitis, meningoencephalitis 
and encephalopathy
Of the 8 reports published up to May 1st 2020, 7 were 
single case reports [26–32] and one a case series (n = 2) 
[33] in the context of oropharyngeal swabs or CSF posi-
tive for SARS-Cov-2 using RT-qPCR. Of the 9 cases, 5 
were females and 3 were males; one did not specify gen-
der; average age 55.5; male 42.0, female 60.8. Clinical 
presentations were generally consistent with the fever and 
confusion commonly described. Meningism was noted in 
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three, headache in four, seizures in three and three exhib-
ited frontal release signs. A single case of acute necrotiz-
ing encephalopathy in a confirmed COVID-19 patient was 
also reported [28].
Imaging failed to demonstrate acute changes in the major-
ity. However, in one case hyperintense signal in the right 
mesial temporal lobe and hippocampus was noted [30] 
whilst hemorrhagic rim enhancing lesions within the bilat-
eral thalami, medial temporal lobes and subinsular regions 
was reported in the case of acute necrotizing encephalopathy 
[28]. EEG was performed in two of the cases presenting with 
seizures as well as one other with encephalopathy [29]; all 
showed generalized slowing.
Of the nine published cases, seven tested CSF for SARS-
Cov-2; two noted that CSF testing was not available at their 
institution [28, 31]. Two cases had positive CSF PCR for 
SARS-Cov-2 [26, 30], five were negative [27, 29, 32, 33]. 
The majority of patients were treated with broad spectrum 
antibiotics and antiviral medications. Two recovered spon-
taneously within 4 days [33] and one showed little response 
to antivirals and hydroxychloroquine but appeared to make 
a dramatic recovery on commencement of high dose steroids 
and was discharged within 2 weeks of presentation [29]. 
Two others who showed little response to initial treatment 
improved with a mannitol infusion [27] and hydroxychloro-
quine [31], respectively. Two patients remained in ITU [30, 
32] and no clear outcome was documented in a further two 
cases [26, 28].
Comment
It is becoming apparent that neurological complications of 
COVID-19 are relatively common together with a suggestion 
that they are seen more frequently with increasing disease 
severity. In common with previous pandemics including 
Zika and SARS-CoV, stroke, GBS and meningoencephalitis 
are emerging as the commonest specific neurological com-
plications but causality remains difficult to prove. Stroke in 
particular may have a plausible biological mechanism whilst 
GBS and meningoencephalitis have a compelling temporal 
relationship and are likely to represent parainfectious phe-
nomenon. However, whether they are specific to COVID-
19 or whether they simply represent the consequence of 
a burden of infection remains unclear. In addition cogni-
tive impairment is also emerging as a common sequelae in 
COVID-19 patients discharged from ITU and we can expect 
an increase in referrals to memory clinics in the short to 
medium term. Only longer term epidemiological studies will 
clarify some of these issues and will need to be supported by 
research on the neurotropic nature of the virus and biological 
mechanisms.
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